Allied Market Research


Recombinant Factor C Assay Market

Recombinant Factor C Assay Market Size, Share, Competitive Landscape and Trend Analysis Report by  Brand, by EndoNext and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Diagnostics and Biotech

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Recombinant factor C is a non-animal-derived reagent used to detect endotoxins in various pharmaceutical products. Furthermore, recombinant factor C assay test is a new age alternative test against limulus amebocyte lysate employed toward endotoxin testing of products for pyrogen. Decrease in the population of horseshoe crab around the globe especially in parts of Asia is a major factor for shift toward recombinant factor C assay. The reagent is activated through endotoxin binding and subsequent substrate cleaving, resulting in release of a fluorogenic compound. The test employs a single step procedure vis-à-vis LAL test. In layman terms, the test does not make use of horseshoe crab’s endotoxin protein as compared to LAL test. One of the major reasons why recombinant factor C assay is at the fulcrum is the dire global demand for search and adoption of an animal-free endotoxin testing procedure.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the recombinant factor C assay market.

Top Impacting Factors

  • PyroGene is anticipated to gain market traction for being a single-step enzymatic process as compared to other multiple step procedures. This is likely to increase overall market share of recombinant factor C assay market.
  • Noval rFC methods are likely to gain huge market potential as being a sustainable solution for endodoxin testing. The method is known to provide higher accuracy and specificity vis-à-vis Limutus Amebocyte Lysate (LAL), which again is a growth factor impacting recombinant factor C assay market.
  • Overall rise in the need for endotoxin detection tests around the globe combined with the need of coming up with more accurate, timely, and efficient tests is a factor driving growth in the market.
  • However, adverse decline in the horseshoe crab and fear of their extinction act as the key restraints of the overall growth of recombinant factor C assay market.

Key Market Trends

United States Pharmacopeia (USP) has reinforced its commitment for introduction and wide spread distribution of recombinant factor C in an attempt to discover new age tests for detection of bacterial endotoxins and other injectable therapeutics.

Recently, Lonza, a global pharmaceutical player announced a new recombinant factor C assay against endotoxin testing of galcanezumab. It was Lonzo who had earlier launched PyroGene in 2003 as well. The development proves that (rFc) is as accurate and specific as LAL-based technique in helping to secure the supply of natural resources.

North America is anticipated to retain its position as the market leader, owing to increase in incorporation on rFC’s in United States pharmaceutical dynamics, strong presence of market players, and robust investments in the field of recombinant technology.

Among the brands, PyroGene is anticipated to account for largest share in global recombinant factor C assay market, as it is the foremost successful assay deployed against LAL tests.

India and China are witnessing market gains, owing to increase in private sector investments into biotechnology field.

Key Benefits of the Report

  • This study presents the analytical depiction of the recombinant factor C assay industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the recombinant factor C assay market share.
  • The current market is quantitatively analyzed to highlight recombinant factor C assay market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the recombinant factor C assay market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Recombinant Factor C Assay Report

  • Which are the leading players active in the recombinant factor C assay market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the recombinant factor C assay market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is recombinant factor C assay?
  • What is the recombinant factor C assay market prediction in the future?
  • What are the current trends and predicted trends?

Recombinant Factor C Assay Market Report Highlights

Aspects Details
By  Brand
  • PyroGene  
  •  PyroGene Bulk
  • PyroGene rFC
By EndoNext
  • EndoZyme II  
  • EndoZyme IIGO
  • EndoLisa
By End User
  • Pharmaceutical Companies    
  •  Biotechnology Companies
  • Medical Device Companies
  • Contract Research Organizations
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Sanofi Pasteur Limited, Glaxosmith Kline Plc., Hyglos GmbH, Pfizer, Novartis AG, Genentech Inc, Eli Lilly, Lonza Group, Merck KGaA, Thermofisher Scientific Inc

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Recombinant Factor C Assay Market

Global Opportunity Analysis and Industry Forecast, 2023-2032